Document Detail


Optimal management of pregnant women with acute venous thromboembolism.
MedLine Citation:
PMID:  10629417     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Venous thromboembolism (VTE) is an important cause of obstetric morbidity and mortality. Its management during pregnancy is problematic because anticoagulants, the cornerstone of initial therapy for VTE, may have significant foetal as well as maternal side effects. Unfractionated heparin has been the anticoagulant of choice in pregnancy; however, there is growing clinical experience with low-molecular-weight heparin (LMWH) in this patient population. A recently published systematic review of the literature suggests that the use of LMWH during pregnancy is not associated with adverse foetal/infant outcomes. Moreover, its long-term use appears to be safe for the mother, as symptomatic osteoporosis, bleeding and heparin- induced thrombocytopenia occurred only infrequently. There are limited data regarding the efficacy of anticoagulant therapy in the treatment of VTE during pregnancy, and treatment recommendations have largely been extrapolated from data in non-pregnant patients and case series of pregnant patients. This paper will briefly review the challenges and areas of controversy associated with the use of anticoagulants in the treatment of pregnancy-associated VTE.
Authors:
S M Bates
Related Documents :
22496697 - Umbilical coiling index as a marker of perinatal outcome: an analytical study.
14998977 - Clinical cure of severe, early onset preeclampsia with low molecular weight heparin the...
9166067 - The value of ventilation-perfusion imaging in pregnancy.
9488787 - Anticoagulants in pregnancy: fetal effects.
20722987 - Prenatal diagnosis and postnatal follow-up of a child with mosaic trisomy 22 with sever...
10710817 - Is apoptosis cause of pre-eclampsia?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Haemostasis     Volume:  29 Suppl S1     ISSN:  0301-0147     ISO Abbreviation:  Haemostasis     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-02-25     Completed Date:  2000-02-25     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0371574     Medline TA:  Haemostasis     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  107-11     Citation Subset:  IM    
Copyright Information:
Copyright 1999 S. Karger AG, Basel
Affiliation:
Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Center, Hamilton, Ont., Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Female
Heparin / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pregnancy
Pregnancy Complications, Cardiovascular / drug therapy*
Venous Thrombosis / drug therapy*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What is the optimal management of pregnant women with valvular heart disease in pregnancy?
Next Document:  Is there a role for antithrombotic therapy in the prevention of pregnancy loss?